Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions  

作　　者：Massimo Giuseppe Colombo Erkin Isakovich Musabaev Umed Yusupovich Ismailov Igor A Zaytsev Alexander V Nersesov Igor Anatoliyevich Anastasiy Igor Alexandrovich Karpov Olga A Golubovska Kulpash S Kaliaskarova Ravishankar AC Sanjay Hadigal 

机构地区：[1]Research and Clinical Center, Department of Medicine, Humanitas Hospital, Rozzano 20089, MI, Italy [2]Research Institute of Virology, Scientific Research Institute of Virology, Tashkent 100194, Uzbekistan [3]Hepatoсenter, Research Institute of Virology, Scientific Research Institute of Virology, Tashkent 100194, Uzbekistan [4]Department of Therapy, Infectious Diseases and Dermatology, Bogomolets National Medical University, Kyiv 01601, Ukraine [5]Department of Gastroenterology and Hepatology, National Research Institute of Cardiology and Internal Diseases, Almaty 050000, Kazakhstan [6]Department Infectious Diseases, Bogomolets National Medical University, Kyiv 01601, Ukraine [7]Department Infectious Diseases, Belarus State Medical University, Minsk 220116, Belarus [8]Hepatology, Ministry of Health, Astana 010000, Kazakhstan [9]Medical Affairs, Mylan Pharmaceuticals Private Limited, Kadubeesanahalli, Bengaluru 560103, India

出　　处：《World Journal of Gastroenterology》2019年第29期3897-3919,共23页世界胃肠病学杂志（英文版）

摘　　要：Globally, 69.6 million individuals were infected with hepatitis C virus (HCV) infection in 2016. Of the six major HCV genotypes (GT), the most predominant one is GT1, worldwide. The prevalence of HCV in Central Asia, which includes most of the Commonwealth of Independent States (CIS), has been estimated to be 5.8% of the total global burden. The predominant genotype in the CIS and Ukraine regions has been reported to be GT1, followed by GT3. Inadequate HCV epidemiological data, multiple socio-economic barriers, and the lack of regionspecific guidelines have impeded the optimal management of HCV infection in this region. In this regard, a panel of regional experts in the field of hepatology convened to discuss and provide recommendations on the diagnosis, treatment, and pre-, on-, and posttreatment assessment of chronic HCV infection and to ensure the optimal use of cost-effective antiviral regimens in the region. A comprehensive evaluation of the literature along with expert recommendations for the management of GT1-GT6 HCV infection with the antiviral agents available in the region has been provided in this review. This consensus document will help guide clinical decision-making during the management of HCV infection, further optimizing treatment outcomes in these regions.Globally, 69.6 million individuals were infected with hepatitis C virus(HCV)infection in 2016. Of the six major HCV genotypes(GT), the most predominant one is GT1, worldwide. The prevalence of HCV in Central Asia, which includes most of the Commonwealth of Independent States(CIS), has been estimated to be5.8% of the total global burden. The predominant genotype in the CIS and Ukraine regions has been reported to be GT1, followed by GT3. Inadequate HCV epidemiological data, multiple socio-economic barriers, and the lack of regionspecific guidelines have impeded the optimal management of HCV infection in this region. In this regard, a panel of regional experts in the field of hepatology convened to discuss and provide recommendations on the diagnosis, treatment,and pre-, on-, and posttreatment assessment of chronic HCV infection and to ensure the optimal use of cost-effective antiviral regimens in the region. A comprehensive evaluation of the literature along with expert recommendations for the management of GT1-GT6 HCV infection with the antiviral agents available in the region has been provided in this review. This consensus document will help guide clinical decision-making during the management of HCV infection, further optimizing treatment outcomes in these regions.

关 键 词：ANTIVIRAL agents COMMONWEALTH of Independent States GENOTYPE Hepatitis C virus SUSTAINED VIROLOGIC response Ukraine 

分 类 号：R[医药卫生]